Asset Details
Do you wish to reserve the book?
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Do you wish to request the book?
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
2012
Overview
A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been shown to improve progression-free survival when added to standard chemotherapy regimens for lymphoma.
Foreword
This
Journal
feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the author's clinical recommendations.
Stage
A 62-year-old man is evaluated for abdominal pain. Computed tomography (CT) shows a 7-cm mesenteric mass. An incisional biopsy reveals a diffuse large B-cell lymphoma, and immunohistochemical staining is positive for the B-cell antigen CD20. The patient is referred to an oncologist. A positron-emission tomographic–CT (PET-CT) scan reveals involvement of additional nodes in the lower chest and abdomen. The serum level of lactate dehydrogenase is twice the upper limit of the normal range. The results of bone marrow biopsy and aspiration are normal on pathological analysis and flow cytometry. The patient reports an unintentional weight loss of 11
1
∕ . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal, Murine-Derived - adverse effects
/ Antibodies, Monoclonal, Murine-Derived - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Cancer
/ Cyclophosphamide - therapeutic use
/ Doxorubicin - therapeutic use
/ Humans
/ Lymphoma
/ Lymphoma, B-Cell - drug therapy
/ Male
/ Practice Guidelines as Topic
